MRTNZ Investment Office · S&P 500 · The 360 Vantage
TECH · NASDAQ-GS
Bio-Techne Corp
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Reference price$72.07As of Jul 28, 2026
Street view
Analyst targets
Published sell-side aggregation—not an MRTNZ forecast.
Forward calendar
Current earnings expectations
Consensus may change until the company reports.
Jun 2026$1.65Street EPS consensus
Jun 2027$1.76Street EPS consensus
Jun 2028$2.01Street EPS consensus
Reported results
Annual financial snapshot
Fiscal period ended Jun 30, 2025.
MetricCurrentPrior
Revenue+5.2% YoY$1.22B$1.16B
Operating income$0.1B$0.21B
Net income$0.07B$0.17B
Operating cash flow$0.29B$0.3B
Capital expenditures($0.03B)($0.06B)
Current context
Related news
Company-linked articles surfaced by Nasdaq.
Evidence
Sources & method
Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →
Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.